Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction  by Berger, Alan K et al.
Acute Myocardial Infarction
Aspirin, Beta-Blocker, and
Angiotensin-Converting Enzyme Inhibitor
Therapy in Patients With End-Stage
Renal Disease and an Acute Myocardial Infarction
Alan K. Berger, MD,*† Sue Duval, PHD,† Harlan M. Krumholz, MD, FACC‡§¶
Minneapolis, Minnesota; and New Haven and Middletown, Connecticut
OBJECTIVES We sought to examine the use and impact of standard medical therapies in patients with
end-stage renal disease (ESRD) faced with an acute myocardial infarction (AMI).
BACKGROUND The poor prognosis of patients in this high-risk population has become increasingly well
recognized.
METHODS Using the ESRD database and the Cooperative Cardiovascular Project (CCP) database, we
identified AMI patients who were receiving either peritoneal dialysis or hemodialysis before
admission. The early administration of aspirin and beta-blockers was compared between
ESRD and non-ESRD patients and the effect of these therapies on 30-day mortality was
evaluated with logistic regression models.
RESULTS The cohort consisted of 145,740 patients without ESRD and 1,025 patients with ESRD.
Aspirin (67.0% vs. 82.4%, p  0.001), beta-blockers (43.2% vs. 50.8%, p  0.001), and
angiotensin-converting enzyme (ACE) inhibitors (38.5% vs. 60.3%, p  0.001) were less
likely to be administered to ESRD patients than to non-ESRD patients. The benefit of these
therapies on 30-day mortality was similar among ESRD patients (aspirin: relative risk [RR]
0.64; 95% confidence interval [CI] 0.50 to 0.80; beta-blocker: RR 0.78; 95% CI 0.60 to 0.99;
ACE inhibitor: RR 0.58; 95% CI 0.42 to 0.77) and non-ESRD patients (aspirin: RR 0.57;
95% CI 0.55 to 0.58; beta-blocker: RR 0.70; 95% CI 0.68 to 0.72; ACE inhibitor: RR 0.64;
95% CI 0.63 to 0.66).
CONCLUSIONS End-stage renal disease patients are far less likely than non-ESRD patients to be treated with
aspirin, beta-blockers, and ACE inhibitors during an admission for AMI. The lower rates of
usage for these medications, particularly aspirin, may contribute to the increased 30-day
mortality. These findings demonstrate a marked opportunity to improve care in this
population. (J Am Coll Cardiol 2003;42:201–8) © 2003 by the American College of
Cardiology Foundation
Approximately 250,000 Medicare beneficiaries are enrolled
in the end-stage renal disease (ESRD) program and receive
either peritoneal dialysis or hemodialysis (1). Cardiovascular
morbidity and mortality remain high among these patients
in spite of advances in medical therapy. Approximately 60%
of deaths reported in the ESRD database are attributed to
either unexpected sudden deaths or arrhythmias. Herzog et
al. (3) recently documented a 59% one-year mortality and a
70% five-year mortality after an AMI among patients
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receiving long-term dialysis. Other than patients with car-
diogenic shock, no other patient population shares such a
high mortality burden. Whether gaps in quality of care for
this vulnerable population contribute to its high AMI
mortality rate is not known.
The rising dialysis rate, particularly among patients over
age 65 years, should serve to focus attention on the patterns
of care in these patients. Historically, these patients have
not been represented in randomized AMI trials evaluating
either medical or interventional strategies. Observational
studies, although limited, have demonstrated a benefit of
revascularization in this cohort in both acute and non-acute
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settings (4–7). In spite of the recognized mortality among
ESRD patients with AMI, a large knowledge deficit per-
sists. No study to date has specifically assessed the use and
effectiveness of standard medical therapies in this cohort.
The Cooperative Cardiovascular Project (CCP) provides
a unique opportunity to evaluate the patterns of care and the
effectiveness of AMI therapies. This nationwide database of
elderly patients includes a large number of patients with
ESRD and describes contemporary care of patients with
AMI (8). Our primary objective was to evaluate the use and
potential benefits of medications in patients treated for
ESRD compared with that observed in patients not receiv-
ing dialysis.
METHODS
Study sample. The patient cohort examined in this study
was derived from the CCP national sample. The CCP
database, collected as part of a national Medicare quality
performance measurement and improvement initiative by
the Centers for Medicare and Medicaid Services, contains
detailed clinical data on 234,769 patients with a principal
discharge diagnosis of AMI (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] 410) between January 1994 and February 1996 (8).
We restricted the study sample to patients age 65 years
and older presenting directly to the index hospital with
clinical evidence of AMI at the time of arrival. We defined
AMI as either an elevation of the creatine kinase-MB
fraction level (5%), an elevation of lactate dehydrogenase
(LDH) levels above normal with reversal of isoenzymes
(LDH1 LDH2), or the presence of at least two of the
following criteria: chest pain during the prior 48 h, a
twofold elevation in creatine kinase, and diagnostic electro-
cardiographic changes (ST-segment elevation or new Q
waves). We excluded patients transferred from another
acute-care facility, because their initial management could
not be ascertained. Repeat admissions for AMI were also
excluded from the analysis.
We predefined three subgroups based on the patient’s
eligibility for specific medical therapies. “Ideal aspirin can-
didates” included those patients without any absolute/
relative contraindications to treatment with aspirin: history
of allergic reaction to aspirin, history of internal bleeding or
bleeding disorder, history of gastrointestinal ulcer, active
bleeding upon arrival, hemoglobin 10 g/dl or hematocrit
30%, platelet count 100,000, comorbid conditions in-
cluding cirrhosis/hepatic failure, leukemia/lymphoma, met-
astatic cancer/terminal illness, and immunosuppression.
“Ideal beta-blocker candidates” included those patients
without absolute/relative contraindications to beta-blockers:
bradycardia (pulse 60 beats/min), hypotension (systolic
blood pressure [SBP] 80 mm Hg), clinical evidence of
cardiogenic shock upon arrival, asthma/chronic obstructive
pulmonary disease, and advanced heart block (second- or
third-degree atrioventricular block). “Ideal angiotensin-
converting enzyme (ACE) inhibitor candidates” included
patients with a documented left ventricular ejection fraction
40% who had no absolute/relative contraindications to
ACE inhibitors, such as history of allergic reaction, of
cardiogenic shock, or of hypotension during hospitalization,
or serum creatinine 2.5 mg/dl (for non-ESRD patients
only).
Data sources. The data elements collected as part of CCP
have been reported previously and include more than 140
variables for each patient (8). Trained medical record
reviewers abstracted patient demographics, past cardiac and
noncardiac history, admission characteristics, diagnostic test
results, and information on in-hospital events and proce-
dures. The high reliability of the abstraction process has
been reported (9).
Enrollment in the ESRD program was determined by
matching patients in the CCP and the U.S. Renal Data
System (USRDS). We were able to match personal identi-
fier numbers for 98% of the patients in the CCP. Patients
with a history of renal transplantation (a small proportion of
the cohort) were excluded from the analysis because their
natural course was not expected to parallel that of patients
receiving either hemodialysis or peritoneal dialysis.
Dates of death in the Medicare Enrollment Database
were derived both from the discharge dates of billing records
indicating a discharge disposition of death and from the
Master Beneficiary Record. The use of the Medicare En-
rollment Database to establish the time of death has been
validated (10).
Statistical analysis. The primary cohort was stratified by
enrollment in the USRDS before the admission for the
index AMI. We evaluated the bivariate association between
ESRD enrollment and the patient demographic and clinical
variables. The rates of usage for aspirin, beta-blocker, and
ACE inhibitor therapy during the index hospitalization
were compared between patients with ESRD and those not
receiving dialysis. For categorical characteristics, compari-
sons were made using the chi-squared test. Comparisons of
continuous parameters were made using the t test and the
results were reported as means  SD.
We used a logistic model to determine the association of
in-hospital aspirin, beta-blocker, and ACE inhibitor ther-
apy with 30-day mortality among patients with and without
ESRD. Demographic characteristics, including age, race,
and gender, were included in the model. Adjustment for
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imbalances in other patient characteristics was performed by
adding covariates from the previously published Global
Utilization of Streptokinase and tPA for Occluded Coro-
nary Arteries (GUSTO)-1 mortality model—SBP at admis-
sion, pulse, location of AMI, Killip class, height, weight,
history of infarction, history of bypass surgery, smoking
status, and the presence or absence of diabetes, hyperten-
sion, and cerebrovascular disease—to the logistic model
(11). As a surrogate for myocardium at risk, we identified
the number of leads with ST-segment elevation and calcu-
lated the sum of ST-segment elevation in all 12 leads of the
initial electrocardiogram. The following variables were also
incorporated into the model: duration of symptoms before
hospital arrival, impaired mobility, the presence of chronic
obstructive pulmonary disease, and left bundle branch block.
For all models, calibration was evaluated by comparing
fitted probabilities of aspirin, beta-blocker, and ACE inhib-
itor use with observed use within deciles of probability (12).
Discrimination was evaluated by calculating an area under
the receiver operating characteristic curve for each model
(13). Multicollinearity among the variables was tested using
the Pearson coefficient. The statistical analyses were per-
formed with the SAS 8.2 software package (SAS Institute,
Cary, North Carolina). Odds ratios were converted to risk
ratios using methods described by Zhang and Yu (14).
RESULTS
Baseline characteristics. The CCP database contains
234,769 abstracted medical records representing 210,996
unique individuals. We were able to identify 206,676
(98.0%) of these individuals for the purpose of determining
those patients enrolled in the USRDS. Of these patients,
157,872 (76.3%) presented directly to the index hospital (n
 180,522) and had clinical evidence of AMI (n 
176,931) upon arrival. The exclusion of 10,826 patients
younger than age 65 years, and 281 patients with a history
of renal transplantation, produced the final cohort of
146,765 patients.
Among the cohort of 146,765 patients, 1,025 (0.70%)
were enrolled in the USRDS. The mean age of patients
enrolled in the USRDS was less than that of patients not
receiving dialysis because enrollment in the USRDS entitles
patients to Medicare coverage regardless of their age.
Patient characteristics varied significantly based on enroll-
ment in the USRDS (Table 1). Patients receiving dialysis
had a higher prevalence of prior cardiovascular disease and
were more likely to have comorbid conditions. They also
had a higher incidence of heart failure, cardiogenic shock,
and cardiac arrest. Dialysis patients were more likely to be
admitted to larger institutions with coronary revasculariza-
tion service on site and less likely to be cared for by
cardiologists.
Application of medical therapy. Standard AMI thera-
pies—aspirin and beta-blockers—were less likely to be used
for patients receiving either peritoneal dialysis or hemodi-
alysis (Fig. 1). Aspirin (62.0% vs. 78.9%, p  0.001),
beta-blockers (37.7% vs. 45.8%, p  0.001), and ACE
inhibitors (37.2% vs. 27.6%, p  0.001) were less likely to
be provided to patients receiving dialysis. There were
100,032 patients deemed ideal for aspirin, 100,445 patients
ideal for beta-blockers, and 30,042 ideal for ACE inhibi-
tors. The rates of usage for aspirin, beta-blockers, and ACE
inhibitors were increased among these restricted cohorts.
However, dialysis patients still remained less likely to receive
any of the medical therapies.
30-day mortality. The 30-day mortality for patients receiv-
ing dialysis was higher than that for patients not receiving
dialysis (29.0% vs. 18.3%, p  0.001). Aspirin use was
associated with lower 30-day mortality both in patients
receiving dialysis (50% relative reduction; 21.1% vs. 41.8%,
p  0.001) and in those not receiving dialysis (63% relative
reduction; 13.5% vs. 36.3%, p  0.001) (Fig. 2). The
restriction of the cohort to the 100,032 patients ideal for
aspirin therapy yielded similar results. Beta-blocker use was
associated with a 40% relative lower 30-day mortality
among patients receiving dialysis (20.5% vs. 34.1%, p 
0.001) and a 56% relative lower mortality among patients
not receiving dialysis (10.9% vs. 24.5%, p  0.001) (Fig. 3).
Among the patients considered ideal for beta-blockers, the
reduction in mortality was also lower for patients receiving
dialysis (34% lower; 20.7% vs. 31.2%, p  0.001) than for
those not receiving dialysis (53% lower; 10.4% vs. 22.0%, p
 0.001). Angiotensin-converting enzyme inhibitor use was
associated with a 48% relative lower 30-day mortality
among patients receiving dialysis (17.3% vs. 33.4%, p 
0.001) and a 27% relative lower mortality among patients
not receiving dialysis (14.9% vs. 20.3%, p  0.001) (Fig. 4).
Among patients considered ideal for ACE inhibitors, the
reduction in mortality was also higher for patients receiving
dialysis (47% lower; 17.9% vs. 33.6%, p  0.007) than for
those not receiving dialysis (33% lower; 16.0% vs. 24.0%, p
 0.001).
After adjusting for baseline demographic and clinical risk
factors, the administration of aspirin was associated with a
similar mortality among patients receiving dialysis (relative
risk [RR] 0.64; 95% confidence interval [CI] 0.50 to 0.80)
and patients not receiving dialysis (RR 0.57; 95% CI 0.55 to
0.58) (Fig. 5). Among patients judged ideal for aspirin
therapy, the benefit of aspirin therapy was similar in the
dialysis group (RR 0.56; 95% CI 0.37 to 0.81) and the
non-dialysis group (RR 0.54; 95% CI 0.52 to 0.56).
The association of beta-blockers with lower mortality was
not as great as that with aspirin. Patients receiving dialysis
had a 22% lower risk (RR 0.78; 95% CI 0.60 to 0.99) in
mortality, whereas those not receiving dialysis had a 30%
risk reduction (RR 0.70; 95% CI 0.68 to 0.72). The benefit
of beta-blocker use was not statistically different between
the dialysis and non-dialysis groups. Restricting the cohort
to patients deemed ideal for beta-blocker use had no
significant effect on the estimates in either the dialysis or
non-dialysis subgroup.
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The ACE inhibitors, in contrast to aspirin and beta-
blockers, appeared to have a greater benefit among patients
receiving dialysis (42% lower risk; RR 0.58, 95% CI 0.42 to
0.77) than among those not receiving dialysis (36% risk
reduction; RR 0.64, 95% CI 0.63 to 0.66). This difference
was not statistically significant. Similar estimates were
identified among patients deemed ideal for ACE inhibitor
therapy.
DISCUSSION
The prognostic significance of dialysis among elderly pa-
tients with AMI has received little attention in spite of the
high mortality among this group. To the best of our
knowledge, our analysis is the first large-scale study to date
that has examined the medical therapy of dialysis patients
with AMI and assessed the association of aspirin and
beta-blocker use on 30-day mortality. Our findings indicate
that aspirin, beta-blocker, and ACE inhibitor therapy exert
a short-term survival benefit among patients with ESRD
similar to that observed in patients not receiving dialysis.
Yet, these medications are far less likely to be provided to
patients receiving dialysis, even among those considered
ideal for these medications, than to patients not receiving
dialysis. Improving the quality of care through the increased
Table 1. Baseline Characteristics Stratified by ESRD Status on Admission
Characteristics No ESRD (n  145,740) ESRD (n  1,025) p Value
Demographics
Age (mean) 76.5  7.4 74.0  6.2 0.001
Age 75 yrs 56.0 41.3 0.001
Median age (25th, 75th) 75 (69, 81) 69 (62, 75)
Female (%) 49.1 39.2 0.001
Caucasian 90.5 73.4 0.001
Risk factors
Hypertension 61.8 80.9 0.001
Diabetes 30.5 46.6 0.001
Smoker 14.7 10.5 0.001
Cardiac history
Myocardial infarction 29.3 36.8 0.001
Heart failure 21.2 39.8 0.001
PTCA 6.6 10.7 0.001
Bypass surgery 12.5 18.7 0.001
Noncardiac history
Stroke 13.9 16.5 0.016
COPD 20.3 21.0 0.56
Dementia 5.8 4.7 0.12
Limited mobility 18.4 30.8 0.001
Nursing home resident 5.4 4.3 0.13
Clinical presentation
Symptom onset 6 h 54.6 47.8 0.001
Shock on arrival 2.2 3.6 0.003
Early cardiac arrest 3.1 5.9 0.001
Height 66.0  4.1 66.1  4.1 0.34
Weight 161.7  35.9 152.3  32.1 0.001
Hypotension (SBP 90 mm Hg) 1.6 4.1 0.001
Bradycardia (HR 60 beats/min) 9.1 5.5 0.001
Killip class 1 50.9 33.4 0.001
Killip class 2 12.1 14.5
Killip class 3 34.8 48.5
Killip class 4 2.2 3.6
Electrocardiographic features
Atrial fibrillation 9.4 10.5 0.19
ST-segment elevation 37.4 31.3 0.001
ST-segment elevation 3 leads 33.5 27.9 0.001
Sum ST-segment elevation 6 mm 18.5 15.0 0.005
Anterior location 46.6 43.2 0.031
LBBB 6.5 7.4 0.26
Hospital characteristics
Annual AMI volume 208  177 255  177 0.001
PTCA service available 41.0 54.2 0.001
Primary MD cardiologist 30.4 17.4 0.001
The highly significant p values derive predominantly from the large size of the patient cohort.
AMI  acute myocardial infarction; COPD  chronic obstructive pulmonary disease; ESRD  end-stage renal disease; HR
 heart rate; LBBB left bundle branch block; PTCA percutaneous transluminal coronary angioplasty; SBP systolic blood
pressure.
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use of aspirin and beta-blockers could therefore reduce
mortality among patients with ESRD presenting with
AMI.
Nearly 300,000 Americans have ESRD, and cardiovas-
cular disease remains the leading cause of mortality among
this group. Unfortunately, there is a paucity of literature
regarding cardiovascular disease, particularly AMI, in this
patient cohort. Randomized clinical trials have typically
excluded high-risk subgroups, particularly patients with
elevated serum creatinine, not to mention those receiving
dialysis. Consequently, much of our knowledge of this
population stems from observational studies (3,7,15).
The association of renal dysfunction and poor outcome
after an AMI has been well documented. A previous
analysis of the CCP by Chertow et al. (7) investigated the
role of revascularization strategies in patients with AMI and
ESRD. In comparison to medical therapy, there was a trend
toward improved survival with coronary artery bypass sur-
gery (RR 0.6; 95% CI 0.3 to 1.1; p  0.09) and no
significant impact on mortality with coronary angioplasty
(RR 1.2; 95% CI 0.8 to 1.8; p  0.5). In contrast to the
current analysis, the diagnosis of ESRD was based solely on
a high serum creatinine; the investigators could not identify
whether the patient had been receiving dialysis before the
admission for AMI. In addition, no information was pro-
vided regarding the use of standard medical therapies such
Figure 1. Aspirin, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors were less likely to be provided to patients with end-stage renal
disease (ESRD) than those without ESRD. In an analysis of patients considered ideal for the individual therapies, the overall administration rates were
higher, but patients with ESRD still remained less likely to receive the therapy than those without ESRD. The p value for each comparison between ESRD
and non-ESRD patients was 0.001.
Figure 2. Thirty-day mortality was dramatically reduced by the administration of aspirin (ASA) during the hospitalization. The p value for each mortality
comparison between patients taking ASA and those not receiving ASA was 0.001. The relative risk reduction in mortality was significantly greater for
patients without end-stage renal disease (ESRD) than for those with ESRD in the entire cohort (63% vs. 50%, p  0.01). After restricting the cohort to
patients ideal for ASA, the reduction in mortality provided by aspirin therapy remained greater in the non-ESRD group, although it was no longer
statistically significant (65% vs. 53%, p  0.10).
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as aspirin and beta-blockers. More recently, Shlipak et al.
(15) demonstrated a correlation between increasing serum
creatinine and one-year mortality after AMI. Unfortunately,
patients with severe renal dysfunction (serum creatinine
4.0 mg/dl) were excluded from that analysis. Using the
USRDS database, Herzog et al. (3) documented a strikingly
high mortality of 59.3% at one year among dialysis patients
who suffered an AMI. The relative risk of mortality was
increased among patients 65 to 74 years of age (RR 1.78;
95% CI 1.69 to 1.88) and more than doubled in patients age
75 years and older (RR 2.09; 95% CI 1.98 to 2.21). Data
regarding medical therapies were not available in the
USRDS database at that time.
The efficacy of aspirin, beta-blockers, and ACE inhibi-
tors among patients with AMI has been established in prior
clinical trials. Early aspirin use reduced 35-day mortality by
23% in a meta-analysis of secondary prevention after AMI
(16). The early use of beta-blockers produced a more
modest impact on short-term mortality, ranging from 0% to
15% (17–19). The benefit of early beta-blocker administra-
tion became more apparent over time, with a 36% relative
reduction in three-month mortality in the Go¨teborg trial
(20). A meta-analysis of the trials of ACE inhibitors in
AMI demonstrated a 7% relative reduction in 30-day
mortality (21).
Patients in our cohort both with and without ESRD
experienced a greater benefit with aspirin, beta-blockers,
and ACE inhibitors than patients in the aforementioned
Figure 3. Thirty-day mortality was dramatically reduced by the administration of beta-blockers during the hospitalization. The p value for each mortality
comparison between patients taking beta-blockers and those not receiving beta-blockers was 0.001. The relative reduction in mortality was significantly
greater for patients without end-stage renal disease (ESRD) than for those with ESRD (56% vs. 40%, p  0.02). After restricting the cohort to patients
ideal for beta-blockers, the relative reduction in mortality provided by beta-blocker therapy was still significantly greater in the non-ESRD group (53% vs.
34%, p  0.03).
Figure 4. Thirty-day mortality was reduced by the administration of angiotensin-converting enzyme (ACE) inhibitors during the hospitalization. The p
value for each mortality comparison between patients taking ACE inhibitors and those not receiving them was 0.001. The relative reduction in mortality
was significantly greater for patients with end-stage renal disease (ESRD) than for those without ESRD (48% vs. 27%, p  0.02). After restricting the
cohort to patients ideal for ACE inhibitors, the relative reduction in mortality provided by ACE inhibitor therapy was still significantly greater in the ESRD
group (47% vs. 33%, p  0.43).
206 Berger et al. JACC Vol. 42, No. 2, 2003
AMI in Dialysis Patients July 16, 2003:201–8
trials. This may reflect the fact that our patient population
was sampled from Medicare beneficiaries, an inherently
older group with more comorbidity and potentially more
advanced cardiovascular disease than patients enrolled in the
randomized clinical trials. Another explanation may lie in
the fact that the CCP sampling time occurred more than a
decade later than the other trials, and patterns of care may
have changed.
We observed a similar absolute reduction in mortality
with aspirin, beta-blocker, and ACE inhibitor therapy when
comparing the dialysis and non-dialysis subgroups. Aspirin
was associated with a 20.7% absolute reduction in 30-day
mortality in dialysis patients and a 22.8% reduction in
non-dialysis patients. The routine use of aspirin could
therefore lead to one life saved for every five patients treated.
Similarly, beta-blocker use was associated with a 13.6%
absolute reduction in mortality in both the dialysis and
non-dialysis patients. Consequently, one life could be saved
for each seven patients treated with beta-blockers. The
ACE inhibitor use was associated with a 16.1% absolute
reduction in 30-day mortality in dialysis patients and a 5.4%
reduction in non-dialysis patients. This translates into the
potential to save one life for every six dialysis patients
treated with an ACE inhibitor.
There are plausible reasons to suspect that aspirin, beta-
blockers, and ACE inhibitors may be less effective in
patients with ESRD than in those without renal insuffi-
ciency. Our data indicate that patients with ESRD have a
greater burden of cardiovascular disease as well as other
comorbid conditions. The presence of these associated
conditions could reduce the impact of these standard med-
ical therapies. Alternatively, patients with ESRD may have
more contraindications to these medications, and thus, the
risks of their use in patients with ESRD could outweigh the
benefits. However, we found a benefit of aspirin, beta-
blockers, and ACE inhibitors in patients with ESRD even
before excluding patients who were not ideal for these
therapies. The fact that these patients achieved the same
benefit as those not receiving dialysis provides a strong
justification for the administration of these medications.
The lower use of both these therapies among dialysis
patients, as demonstrated in our findings, represents a focus
for improvement in quality of care. Future initiatives, both
within the USRDS and at the local hospital level, should
incorporate processes that guarantee a higher rate of usage
of these medical therapies among dialysis patients.
Study limitations. Several issues should be considered in
interpreting our study. Because this was an observational
study based on a retrospective chart analysis, unmeasured
factors in the CCP could have influenced our findings. To
address this issue, we used methods that minimize the
problems inherent in drawing inferences from observational
data (22). Although statistical modeling techniques cannot
completely control for this potential bias, the large number
of variables available in the CCP allowed adjustment for
many patient characteristics. Given the magnitude of sur-
vival benefit associated with aspirin, beta blockers, and ACE
inhibitors in the ESRD population, these residual con-
founding factors would probably have a minimal impact on
our results. Second, our results are based on data that were
collected between 1994 and 1996, and improvements in
health care delivery since that time may have served to
Figure 5. Effects are illustrated for the entire cohort as well as patients deemed ideal for each of the therapies. The mortality models showed good
discrimination; the area under the receiver operating characteristic curve ranged from 0.75 to 0.78 for the 30-day mortality models. In assessing the goodness
of fit in both models, there was less than a 10% difference between observed and expected mortality within each decile of probability for each model. The
Pearson coefficient was 0.30 between the treatment variables and all other covariates. Triangles  patients with end-stage renal disease (ESRD); circles
 patients without ESRD. ACE  angiotensin-converting enzyme; ASA  aspirin; BB  beta-blocker.
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increase the use of aspirin, beta-blockers, and ACE inhib-
itors among patients with ESRD. Nevertheless, this study
provides the first comprehensive analysis of AMI therapies
among patients with ESRD.
Conclusions. The extraordinarily high mortality of ESRD
patients should serve to focus greater attention on their
medical care. Our findings suggest there is an opportunity to
improve the quality of care and, consequently, the survival
among patients with ESRD. Aspirin, beta-blockers, and
ACE inhibitors should be administered to dialysis patients
without absolute contraindications to these therapies, and
the medications should be provided early in the course of
infarction. The data show a clear benefit of these medica-
tions among dialysis patients at 30 days.
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